| Apolipoprotein E (ApoE) | |
|---|---|
| Gene | APOE |
| UniProt | P02649 |
| PDB | 1GS9, 1OR2, 2KC3 |
| Mol. Weight | 34 kDa |
| Localization | Secreted (lipoproteins), extracellular |
| Family | Apolipoprotein family |
| Diseases | Alzheimer's Disease, Cardiovascular Disease, Dementia with Lewy Bodies |
Apolipoprotein E (Apoe) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Apolipoprotein E (ApoE) is a 34 kDa polymorphic glycoprotein essential for lipid transport and neuronal homeostasis in the central nervous system. Encoded by the [APOE--TEMP--/genes)--FIX-- gene on chromosome 19, ApoE is primarily produced by astrocytes and microglia, with lesser contributions from neurons under stress conditions. Its three major isoforms—ApoE2, ApoE3, and ApoE4—differ by single amino acid substitutions at positions 130 and 176 (Cys/Arg), resulting in profound differences in lipid binding affinity, receptor interactions, and aggregation propensity. ApoE4 represents the strongest known genetic risk factor for late-onset Alzheimer's disease, increasing risk by 3-4 fold in heterozygotes and 10-15 fold in homozygotes.
The human APOE gene exhibits polymorphism with three common alleles (ε2, ε3, ε4) encoding three protein isoforms:
| Isoform | Amino Acids (130, 176) | Frequency | AD Risk |
|---|---|---|---|
| ApoE2 | Cys130, Cys176 | ~8% | Protective |
| ApoE3 | Cys130, Arg176 | ~78% | Baseline |
| ApoE4 | Arg130, Arg176 | ~14% | Increased |
ApoE2 (Cys130, Cys176) has reduced lipid binding affinity and is associated with lower LDL receptor binding efficiency. While protective against AD, ApoE2 homozygotes have increased risk for type III hyperlipoproteinemia.
ApoE3 (Cys130, Arg176) represents the most common isoform with intermediate function. It efficiently binds to LDL receptors and mediates lipid transport optimally.
ApoE4 (Arg130, Arg176) exhibits distinct structural properties including a domain interaction between Arg130 and Arg176 that alters protein folding. This results in:
ApoE is the primary apolipoprotein in the brain, essential for:
Cholesterol homeostasis — ApoE-containing lipoproteins deliver cholesterol to neurons via LDLR and LRP1 receptors, supporting membrane synthesis and synaptic plasticity.
Phospholipid transfer — Facilitates redistribution of phospholipids between cells and myelin maintenance.
Lipid raft modulation — Influences neuronal membrane microdomain composition affecting signal transduction.
Synaptic plasticity — Supports long-term potentiation and memory formation through cholesterol delivery to synapses.
Neurogenesis — Promotes neural stem cell proliferation and differentiation in the subventricular zone and hippocampus.
Oxidative stress protection — Antioxidant properties mitigate ROS-induced neuronal damage.
Blood-brain barrier maintenance — Supports endothelial cell function and tight junction integrity.
ApoE plays a critical role in amyloid-β (Aβ) metabolism through multiple mechanisms:
Aβ Binding and Aggregation
Aβ Clearance Pathways
Aβ Production Modulation
Beyond Aβ, ApoE4 exacerbates tau pathogenesis:
ApoE4 drives neuroinflammatory responses:
ApoE mimetic peptides — Small peptides mimicking ApoE functional domains promote Aβ clearance
ApoE aggregation inhibitors — Small molecules preventing ApoE4 oligomerization
Gene therapy — AAV-mediated APOE2 delivery to CNS (currently in clinical trials)
Receptor modulators — Agonists for LDLR and LRP1 to enhance Aβ clearance
ApoE status influences biomarker interpretation:
Apolipoprotein E (Apoe) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Apolipoprotein E (Apoe) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Huang Y, Mucke L, Alzheimer mechanisms and therapeutic strategies, Cell (2012)
Liu CC, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat Rev Neurol (2013)
Verghese PB, ApoE4 and Copper Interact to Elevate Neurodegeneration, Neuron (2013)
Zhao N, Apolipoprotein E4 Impairs Neuronal Insulin Signaling and Glucose Transport, PLoS One (2015)
Friedman LG, Apolipoprotein E4 and Astrocyte Lipid Metabolism, Biol Psychiatry (2019)